Avidity Biosciences, Inc.’s Post

Later today as part of #FierceJPMWeek, I look forward to sharing how at Bristol Myers Squibb, our strategic research framework is helping us meet a challenge felt across the industry – improving R&D productivity for the ultimate benefit of patients. Learn more: bit.ly/48Oa85S.   Our focus on three key principles – harnessing causal human biology, matching therapeutic modality to molecular mechanism of action and focusing on a path to clinical proof-of-concept –will enable us to continue advancing transformative science for patients.   If you’re attending #JPM24 or Fierce JPM Week, what have been your biggest takeaways for R&D so far?   #BMS_Employee

Deep Dive: Precision Immunology From autoimmune to anticoagulatory conditions, we explore how precision medicine is reshaping the treatment landscape by decoding the complexities of immune-mediated diseases. Learn how advancements in big data analytics and computational power are enabling us to tailor therapies for individual patients, ensuring personalized treatment plans with improved efficacy and safety. In this deep dive, we examine the transformative impact of precision immunology on patient care, from the identification of immune-specific subpopulations to the development of companion diagnostics for guided therapies. Discover how these innovative approaches are driving forward the future of healthcare, paving the way for a new era of personalized medicine. Don't miss out on this insightful read!

Researchers with QUEST in Berlin have developed and tested a new approach to improving clinical trial transparency. It involves sending individual investigators ‘report cards’ that detail which aspects of trial registration and reporting they did well on in the past, where they fell short of global best practices, and practical advice on how to improve their performance in future. This approach could be adopted by: - research institutions - research funders - clinical trial registries More details here: https://lnkd.in/dvPxCZaD #clinicaltrials #openscience

#rAj_Tspin, a soluble recombinant peptide from Apostichopus japonicus, can inhibit the integrin β1 (ITGB1)/FAK/AKT signaling pathway in #hepatocellular_carcinoma (HCC) via cell #epithelial_mesenchymal_transition (EMT) and #apoptosis. #Zyxin (ZYX) is a focal adhesion protein that is considered a novel mediator of EMT and apoptosis. However, the inhibitory mechanisms of rAj-Tspin in HCC and whether it is related to ZYX are unclear. In this study, results revealed that rAj-Tspin strikingly reduced the viability promoted the apoptosis of Huh7 cells, and inhibited HCC tumor growth in nude mice. rAj-Tspin inhibited ITGB1 and ZYX protein expression in vivo and in vitro in a dose-dependent manner. Mechanistically, the FAK/AKT signaling pathway and the proliferation and invasion of #HCC cells were suppressed upon ITGB1 and ZYX knockdown. Moreover, the effect of ITGB1 overexpression on the growth of HCC cells was inhibited by rAj-Tspin. In contrast, the promoting effect of ITGB1 overexpression could be inhibited by ZYX knockdown. ZYX knockdown did not affect ITGB1 expression. These findings suggest that ZYX is required for the indispensable role of ITGB1 in rAj-Tspin-alleviated HCC and provides an important therapeutic target for HCC. In summary, the anti-HCC effect of #rAj_Tspin potentially involves the regulation of the #ITGB1/ZYX/FAK/AKT pathway, which in turn impacts #EMT and #apoptosis. REF: https://lnkd.in/dDXA4Jg7 #rAj_Tspin #Epithelial_mesenchymal_transition #apoptosis #Zyxin #Non_alcoholic_fatty_liver_disease #NAFLD #Hepatocellular_Carcinoma #HCC_Awareness #liver

#Announcement from Frederick National Laboratory for Cancer Research You are invited to join the user group for the #NEW Computational Resources for Cancer Research portal that launched at #AACR!   1. The first user group meeting will be held on Tuesday, May 14, 2024, 3:00 pm – 4:30 pm ET. This meeting is planned for 90 minutes; future meetings may be less. 2. We will start the discussion about cancer computing needs at the first user group meeting. 3. For reference, see the portal launch announcement, below, and watch for the calendar invitation coming soon! Please join us!   Who: Cancer data scientists, students, and biomedical researchers who want to help increase the scientific impact and usability of the resources on the portal. All #career levels are encouraged to participate: students, 1st year investigators, professors and PIs, physician-scientists, and clinicians!   What: First computational.cancer.gov user group meeting Purpose: Help increase the scientific impact and usability of the resources on the new portal! Current resources include computational models, scientific software, data and datasets, educational use cases, publications, collaborations, emerging areas, and events.   When: Tuesday, May 14, 2024, 3:00 pm – 4:30 pm ET                                                                                                                                                                                                                                                                 Link: Meeting link Meeting ID: 216 030 092 621 Passcode: pwetT7

🗣 Our Director of Evaluation, Clara M. Pelfrey shares her story about collaborating with other CTSA hubs by investigating and sharing case studies of successful translational science projects. "We have been developing a process for and conducting case studies of successful research since 2017 to learn about the clinical and translational process - how it works when it is working well, as well as discovering the challenges and how those obstacles were overcome, leading to discoveries and improved health." 📰 Read the full article here: https://lnkd.in/ddTbecZj #TranslationalScience #CTSA #ClinicalResearch #HealthInnovation #CaseStudies #ScientificResearch #Collaboration CTSA CCOS Center; National Center for Advancing Translational Sciences (NCATS); National Institutes of Health

🔬 Just Released: OniX OnPoint Issue #11 - Week 11, 2024 Excited to share our latest deep dive into groundbreaking biotech innovations! This week's issue spotlights crucial developments in TREM2 research and neurodegenerative diseases. Highlights include: - Discovery of Aplp1 and Lag3 interaction as a new target in α-synucleinopathies - AI-predicted structures unlocking new drug discovery opportunities for protein kinases - Insights into how glycolytic flux drives retinal progenitor differentiation via Wnt signaling - Identification of specialized immune cells in metastatic cancer spread - Innovative use of placenta donations for healing burns and wounds Our comprehensive analysis covers everything from technology transfer and sponsored projects to startup innovations and the latest research breakthroughs. Want More? Join Our Community! https://lnkd.in/edUVWht9 🎉 Excited about these breakthroughs? There's so much more to explore! - Sign up for our newsletter: Get free access to our Table of Contents and stay in the loop with the latest biotech trends. - Go Premium: Unlock full access to all our in-depth content with our yearly plan. Don't miss out on the cutting-edge insights that could shape the future of biotech. Join us today and be part of the innovation journey! 🔗 Explore our plans and start your biotech adventure #Biotech #Innovation #Research #Neuroscience #DrugDiscovery #TREM2 #BiotechNews

Are you interested in #DecentralizedClinicalTrials? Of COURSE you are! And so is the National Center for Advancing Translational Sciences (NCATS). We issued a Request For Information, and *you* responded!! Christopher Hartshorn, Pablo Cure, Thomas C. Radman, and Terry Rudd did the hard work of putting the RFI out into the world, taking in everything you told us, analyzing it, preparing a report of the findings, and getting the report to you. Don't you want to know what we learned? Of COURSE you do! BOOM! https://lnkd.in/e5JEfkUJ

Shaping the Future of Life Sciences & Healthcare - in partnership with Manchester University NHS Foundation Trust (MFT) and QIAGEN🔬📹 Headquarterd in Citylabs 2.0, QIAGEN is at the forefront of pioneering advancements in genomics and molecular diagnostics, and they’re driving forward crucial research that has the potential to transform patient care worldwide. The collaboration between Qiagen and MFT is enabling the rapid development of diagnostic tests and personalised medicine, pushing the boundaries of what’s achievable in healthcare. Directly facilitated through our strategic partnership with MFT, businesses like Qiagen are not only making strides in science; but are also laying the foundation for life-changing discoveries that will impact patients globally. Watch the first in a series of videos featuring customers from our Citylabs and Manchester Science Park campus', and see how this powerful partnership between Bruntwood SciTech, MFT and our customers is making a difference! MFT Research and Innovation #LifeSciences #HealthcareInnovation #BruntwoodSciTech #ManchesterInnovation #Qiagen #MFT #ScienceAndTechnology #InnovationHub

Come see the power of multi-omics from the most experienced partner for gene expression at the single-molecule/single-cell level - RNAscope